Impact of CYP2C19 variants on clinical efficacy of clopidogrel and one-year clinical outcomes in coronary heart patients undergoing percutaneous coronary intervention

Impact of CYP2C19 variants on clinical efficacy of clopidogrel and one-year clinical outcomes in coronary heart patients undergoing percutaneous coronary intervention

The impact of pharmacogenetic variants of cytochrome P450 2C19 (CYP2C19) on clopidogrel-mediated effects on platelet inhibition, inflammatory response and endothelial function, as well as risk of major adverse cardiovascular events (MACE), in coronary heart patients undergoing percutaneous coronary...

Full description

Bibliographic Details
Main Authors:	Hong Sun, Qiang Qu, Zhen Fan Chen, Sheng-Lan Tan, Hai-Jun Zhou, Jian Qu, Hui Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2016-11-01
Series:	Frontiers in Pharmacology
Subjects:	antiplatelet therapy clopidogrel CYP2C19 PCI Metabolizers
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00453/full

Similar Items

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
by: Ahmed Shawky, et al.
Published: (2023-05-01)

CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel
by: Yu-Wei Chen, et al.
Published: (2022-08-01)

Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease
by: Yujing Cheng, et al.
Published: (2023-01-01)

ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY?
by: S. J. Martsevich
Published: (2016-01-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
by: Amber L. Beitelshees, et al.
Published: (2022-02-01)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
by: Sherry-Ann Brown, et al.
Published: (2018-01-01)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
by: Seyed abbas Mirabbasi, et al.
Published: (2017-07-01)

Effect of <em>CYP3A4</em>*22 and <em>PPAR-α</em> Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention
by: Thomas O. Bergmeijer, et al.
Published: (2020-09-01)

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)
by: Mohammed Ahmed Akkaif, et al.
Published: (2021-04-01)

Pharmacodynamic safety of clopidogrel monotherapy in patients under oral anticoagulation with a vitamin K antagonist undergoing coronary stent implantation
by: Christian Valina, et al.
Published: (2019-08-01)

Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome - case report and literature review
by: Rahel Tekeste, et al.
Published: (2022-04-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Platelet reactivity after clopidogrel loading in patients with acute ischemic stroke
by: Yukiko Enomoto, et al.
Published: (2022-08-01)

CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS
by: R. Rahmatini, et al.
Published: (2018-04-01)

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
by: Daniele Jones, et al.
Published: (2024-01-01)

THE MODERN ASPECTS OF CLOPIDOGREL USE
by: E. N. Dankovtseva, et al.
Published: (2016-01-01)

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015-12-01)

EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: A. L. Alyavi, et al.
Published: (2016-01-01)

THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS
by: O. V. Gaisenok
Published: (2016-01-01)

Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance
by: Usman Nawaz, et al.
Published: (2023-11-01)

Ticagrelor versus clopidogrel in the management of acute myocardial infarction
by: Candice Volney, et al.
Published: (2019-07-01)

Effect of ticagrelor versus clopidogrel after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome—propensity score matching analysis
by: Yinan Zhao, et al.
Published: (2024-01-01)

Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis
by: Di Liu, et al.
Published: (2023-10-01)

Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
by: Bin YANG, et al.
Published: (2018-07-01)

Ulcerative livedoid vasculopathy responding to clopidogrel
by: Elaine Kunzler, BS, et al.
Published: (2018-03-01)

CYP2C19*1 and CYP2C19*2 Polymorphism in Turkish Patients Being Diagnosed with Stable Coronary Artery Disease and Using Clopidogrel
by: Ramazan Sabırlı, et al.
Published: (2021-03-01)

Clopidogrel versus ticagrelor in East Asian patients aged 75 years or older with acute coronary syndrome: observations from the GF-APT registry
by: Ziwei Xi, et al.
Published: (2022-11-01)

Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease
by: Chor-Cheung Tam, et al.
Published: (2022-12-01)

Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes
by: Mouhrach I, et al.
Published: (2023-10-01)

COMPARISON OF THE ORIGINAL (PLAVIx) AND GENERIC (CLAPITAx) CLOPIDOGREL ON PLATELET AGGREGATION: ObSERVATIONAL STUDY
by: A. S. Skotnikov, et al.
Published: (2018-05-01)

Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report
by: Jianhong Wu, et al.
Published: (2023-10-01)

Double‐Dose Versus Standard‐Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
by: Matthias Bossard, et al.
Published: (2017-11-01)

Real-world experience of clinical management with antiplatelet and lipid-lowering therapy in post acute coronary syndrome patients in Indian setting
by: M S Hiremath, et al.
Published: (2021-01-01)

Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis
by: Mohitosh Biswas, et al.
Published: (2021-07-01)

The correlation between CYP2C19 Polymorphisms and recurrent risk in Patients with Ischemic Stroke treated with Clopidogrel in Kurdistan region-Iraq
by: Hind Salim Jardaq, et al.
Published: (2022-12-01)

Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01)

Association of ABCC2 polymorphism with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention
by: Lida Chen, et al.
Published: (2022-10-01)

The association between CYP2C19 genetic polymorphism and prognosis in patients receiving endovascular therapy
by: Wei Li, et al.
Published: (2024-01-01)

Ticagrelor versus clopidogrel after intracranial stent angioplasty: a real-world study
by: Lili Sun, et al.
Published: (2023-08-01)

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
by: Mohamed Farag, et al.
Published: (2022-10-01)